Creighton University, Omaha, NE 68178, USA.
Drug Dev Ind Pharm. 2010 Jan;36(1):1-30. doi: 10.3109/03639040903092319.
Pulmonary drug delivery is an accepted route of drug administration for the management of lung conditions and diseases as well as an evolving route of administration for the systemic delivery of agents. Many inhaled drugs pose formulation and delivery challenges in part because of poor aqueous solubility. The influence of poor aqueous solubility and formulation-based solubility enhancements on the pharmacokinetic profile of inhaled agents was reviewed.
A systematic review was performed to identify literature that reported pharmacokinetic findings following the pulmonary delivery of a poorly water-soluble agent.
The influence of solubility and formulation-based solubility enhancements on pharmacokinetic parameters following inhalation of corticosteroids, antifungals, oligopeptides, and opioids, was compiled.
Poor aqueous solubility did not uniformly affect the pharmacokinetic profile for inhaled agents. Physicochemical and formulation-based solubility enhancement did affect drug absorption from the lungs. Numerous drug- and formulation-dependant pharmacokinetic effects were identified.
肺部给药是一种被认可的肺部疾病治疗药物给药途径,也是一种用于全身输送药物的新兴给药途径。许多吸入药物由于水溶性差而存在制剂和输送方面的挑战。本文综述了水溶性差和基于制剂的溶解度增强对吸入药物药代动力学特征的影响。
进行了系统评价,以确定报告肺部输送水溶性差的药物后药代动力学发现的文献。
编译了水溶性和基于制剂的溶解度增强对吸入皮质激素、抗真菌药、寡肽和阿片类药物的药代动力学参数的影响。
水溶性差并不统一地影响吸入药物的药代动力学特征。物理化学和基于制剂的溶解度增强确实会影响肺部的药物吸收。确定了许多与药物和制剂相关的药代动力学影响。